Allergic and cutaneous reactions following inactivated SARS‐CoV‐2 vaccine (CoronaVac ^® ) in healthcare workers

Abstract

and one-third (33.9%) were 'not confident' or 'not at all confident' in managing skin conditions in patients with SOC (Fig. 1c). Lack of exposure to patients with SOC was cited by 60.7% of participants as the biggest challenge to looking after these patients (Fig. 1d), which was not an unexpected finding, as 67.9% of respondents estimated that < 5% of their patients had SOC. Specific conditions that were noted to be difficult to diagnose or manage included (i) inflammatory dermatoses (n = 29) such as atopic dermatitis and lupus, (ii) pigmentary disorders (n = 16) such as melanocytic naevi and vitiligo, and (iii) keloid scarring (n = 4). Suggested solutions to improving knowledge included dedicated study days, online resources, cultural training and dedicated teaching clinics.This study shows that Irish dermatologists have low confidence in diagnosing and managing conditions in people with SOC. This is consistent with a previous study showing that only 56% of Australian dermatologists were confident in diagnosing and 75% confident in managing common dermatoses in patients with SOC. 2 This discrepancy in confidence between skin types is important as patients with more darkly pigmented skin are more likely to have negative outcomes from dermatological disease, including melanoma. 3 It has recently been shown that white skin is over-represented in images of COVID-19associated eruptions. 4 With growing awareness of racial equity in medicine, 5 efforts are being made to increase the availability of clinical images highlighting the appearance of dermatoses in SOC. Resources to improve education in SOC include the Skin Diversity Subcommittee of the British Association of Dermatologists, and the associations Skin Deep (https://dftbskindeep.com/) and Skin of Color Society (https://skinofcolorsociety.org/).In conclusion, Irish dermatologists have low confidence with skin pathology in SOC, and specific training could reduce this disparity.

Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines

“…Considering the additive components in CoronaVac, it does not contain the ones (except sodium chloride) similar in the drugs which the patients had a HSR history with. However, there are some reports demonstrating HSRs to CoronaVac [ 33 , 34 , 35 ]. Urticaria was detected as the most common cutaneous reaction in healthcare workers vaccinated with CoronaVac [ 33 ].…”

“…However, there are some reports demonstrating HSRs to CoronaVac [ 33 , 34 , 35 ]. Urticaria was detected as the most common cutaneous reaction in healthcare workers vaccinated with CoronaVac [ 33 ]. Most of the HSRs in a latter study were mild except 1 case of anaphylaxis.…”

Cutaneous reactions after COVID‐19 vaccination in Turkey: A multicenter study

“…In a study by Durmaz et al, who used an e‐mail survey to evaluate 221 healthcare professionals vaccinated with CoronaVac, 33 cutaneous reactions were reported, with the most common being urticaria. 6 In two case series, one including seven patients 8 and the other including six patients, 7 urticaria/angioedema was the most observed cutaneous reactions. In the current study, after the CoronaVac vaccine, type 1 immediate type reactions were observed, such as urticaria/angioedema and anaphylaxis and type 4 delayed‐type reactions, including petechial rash, dyshidrotic eczema, lichenoid reaction, erythema multiforme, contact dermatitis, delayed large local reaction, symmetrical drug‐related intertriginous and flexural exanthema, and maculopapular rash.…”

“… 1 , 2 Population‐based, 3 hospital‐based, 4 and international registry‐based 5 studies have also been undertaken to investigate the cutaneous adverse reactions to the BioNTech vaccine. However, there are only small‐scale studies 6 and case series 7 , 8 concerning the cutaneous adverse reactions to the CoronaVac vaccine.…”

Pityriasis rubra pilaris in association with inactivatedSARS‐CoV‐2 vaccine (CoronaVac)

“…Most of reactions improved within few weeks of onset without treatment. 1 However, there are no reports of the inactivated vaccine as a trigger of pityriasis rubra pilaris (PRP).…”